AstraZeneca Discontinues Brazikumab Inflammatory Bowel Disease Development Program
By Anthony O. Goriainoff
AstraZeneca said Thursday that it was discontinuing the brazikumab inflammatory bowel disease development program after reviewing its development timeline as well as the context "of a competitive landscape that has continued to evolve."
The Anglo-Swedish pharma giant said the timeline had been hurt by delays that couldn't be mitigated following global events and that no safety concerns were identified for patients in these trials.
The company said that AbbVie had partly funded the program and that this funding will now stop.
AstraZeneca said that the program was investigating an anti IL-23 monoclonal antibody for the treatment of Crohn's disease and ulcerative colitis.
Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
June 01, 2023 02:44 ET (06:44 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
Will Earnings From These 10 AI Stocks Live Up to the Hype?
-
What’s Happening In the Markets This Week
-
What the Next Bitcoin Halving Means for ETF Investors
-
Going Into Earnings, Is Microsoft a Buy, a Sell, or Fairly Valued?
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings Beat Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth
-
10 Best Blue-Chip Stocks to Buy for the Long Term
-
After Earnings, Is Netflix Stock a Buy, a Sell, or Fairly Valued?
-
ServiceNow Earnings: Strong Quarter With In-Line Guidance and Increasingly Attractive Valuation
-
Ford Earnings: Pro Continues to Impress While EV Costs Are Contained
-
Boeing Earnings: Paying for Mistakes Made Long Ago, Taking Back the Factory Floor